Emergency COVID-19 Variant Supplement for Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)

亚特兰大微系统工程护理点技术中心 (ACME POCT) 的紧急 COVID-19 变异补充品

基本信息

  • 批准号:
    10476947
  • 负责人:
  • 金额:
    $ 1548.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-18 至 2023-05-31
  • 项目状态:
    已结题

项目摘要

The advent of point-of-care (POC) diagnostic capabilities has enabled rapid and timely clinical evaluation in the physician's office, an ambulance, the home, the field, or in the hospital and has the potential to significantly impact health care delivery. In cardiology, pulmonology/critical care, and hematology, POC testing plays an especially significant role as the heart and lungs are among the most vital of organs necessitating real time diagnosis and rapid management during critical illnesses, while pathologic alternations in blood are associated with critical, systemic illness. One class of novel medical technologies that is showing promise for POC applications are microsystems-engineered technologies, that is, microchip-enabled devices ranging from microelectromechanical systems (MEMs)-based sensors, microfluidics, to even smartphone-based systems. Notable for their small size and power requirements, microchip-based systems provide the portability that is vital for POC testing. In addition, the capability of microsystems to convert sound and movement into electrical signals enable these technologies to be ideal devices to sense the dynamics of the lungs and heart and therefore to diagnose and monitor pulmonary and cardiac disorders. Moreover, microsystems engineering has brought forth the field of microfluidics, which is steadily finding applications for blood-based diagnostics, and therefore, hematologic applications. To that end, per the NHLBI's U54 POCTRN guidelines, the overall goal of the Atlanta Center for Microsystems Engineered POC Technologies (ACME POCT) is to assist and enable inventors from across the country who have developed microsystems-based POC technologies for cardiac, pulmonary, hematologic and sleep applications that are beyond proof-of-concept to define their specific clinical needs, conduct clinical validation, and refine their technology, with the objective of accelerating the path to translation and clinical adoption and directly addressing the barriers thereof. The ACME POCT uniquely leverages Atlanta's nationally top-ranked clinical programs at Emory University's hospitals and Children's Healthcare of Atlanta, one of the nation's largest pediatric hospital systems, as well the internationally acclaimed microsystems engineering expertise at Georgia Tech, which includes the Institute for Electronics and Nanotechnology (IEN), and other one-of-a-kind medical device prototyping, innovation, and testbed facilities. The ACME POCT PI's uniquely balance the engineering and clinical sides of the Center and comprise Wilbur Lam, MD, PhD, a clinical hematologist at Emory and Georgia Tech bioengineer with expertise in POC diagnostic development and commercialization, Oliver Brand, PhD, a renowned microsystems engineer and head of Georgia Tech's IEN, and Greg Martin, MD, MSc, a clinical pulmonologist at Emory and head of clinical research in Atlanta's NIH-funded CTSA. Importantly, the leadership of the ACME POCT has a history of collaboration and track record in managing Centers that have fostered medical device development.
点护理(POC)诊断能力的出现使快速和及时的临床评估成为可能

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wilbur A Lam其他文献

Effect of Epitope Specific Antibodies on Single Platelet Physiology with Implications for Immune Thrombocytopenia Purpura
  • DOI:
    10.1182/blood-2022-159547
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Nina Shaver;Oluwamayokun Oshinowo;Meredith E. Fay;David R. Myers;Wilbur A Lam
  • 通讯作者:
    Wilbur A Lam

Wilbur A Lam的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Wilbur A Lam', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10265612
  • 财政年份:
    2020
  • 资助金额:
    $ 1548.19万
  • 项目类别:
Engineering biophysical microtechnologies for hematologic applications in health and disease
工程生物物理微技术在健康和疾病中的血液学应用
  • 批准号:
    10579951
  • 财政年份:
    2019
  • 资助金额:
    $ 1548.19万
  • 项目类别:
Engineering biophysical microtechnologies for hematologic applications in health and disease
工程生物物理微技术在健康和疾病中的血液学应用
  • 批准号:
    10350610
  • 财政年份:
    2019
  • 资助金额:
    $ 1548.19万
  • 项目类别:
Engineering biophysical microtechnologies for hematologic applications in health and disease
工程生物物理微技术在健康和疾病中的血液学应用
  • 批准号:
    9898450
  • 财政年份:
    2019
  • 资助金额:
    $ 1548.19万
  • 项目类别:
SBIR phase II: A personalized, non-invasive hemoglobin level monitoring and management platform for chronic anemia patients.
SBIR II 期:针对慢性贫血患者的个性化、无创血红蛋白水平监测和管理平台。
  • 批准号:
    10458078
  • 财政年份:
    2018
  • 资助金额:
    $ 1548.19万
  • 项目类别:
SBIR phase II: A personalized, non-invasive hemoglobin level monitoring and management platform for chronic anemia patients.
SBIR II 期:针对慢性贫血患者的个性化、无创血红蛋白水平监测和管理平台。
  • 批准号:
    10325763
  • 财政年份:
    2018
  • 资助金额:
    $ 1548.19万
  • 项目类别:
Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)
亚特兰大微系统工程护理点技术中心 (ACME POCT)
  • 批准号:
    10715493
  • 财政年份:
    2018
  • 资助金额:
    $ 1548.19万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10715494
  • 财政年份:
    2018
  • 资助金额:
    $ 1548.19万
  • 项目类别:
Redefining Clinical Viscosity in Sickle Cell Diseaseby Leveraging Microfluidic Technologies
利用微流体技术重新定义镰状细胞病的临床粘度
  • 批准号:
    10022309
  • 财政年份:
    2018
  • 资助金额:
    $ 1548.19万
  • 项目类别:
Technology Development Core
技术开发核心
  • 批准号:
    10251185
  • 财政年份:
    2018
  • 资助金额:
    $ 1548.19万
  • 项目类别:

相似海外基金

WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 1548.19万
  • 项目类别:
    Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 1548.19万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 1548.19万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 1548.19万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 1548.19万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 1548.19万
  • 项目类别:
    EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 1548.19万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 1548.19万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 1548.19万
  • 项目类别:
    Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 1548.19万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了